Abstract
Angiotensin-converting–enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) are considered equivalent for first-line treatment of patients
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have